166
Participants
Start Date
September 22, 2021
Primary Completion Date
March 31, 2025
Study Completion Date
April 7, 2027
Talquetamab
Talquetamab will be administered subcutaneously.
Carfilzomib
Carfilzomib will be administered as an IV infusion.
Daratumumab SC
Daratumumab will be administered subcutaneously.
Lenalidomide
Lenalidomide will be self-administered orally.
Pomalidomide
Pomalidomide will be self-administered orally.
Cliniques Universitaires St-Luc, Brussels
Wollongong Hospital, Wollongong
UZA, Edegem
UZ Leuven, Leuven
Alfred Health, Melbourne
St Vincents Hospital Melbourne, Fitzroy
Gold Coast University Hospital, Southport
UZ Gent, Ghent
Mt. Sinai School of Medicine, New York
Weill Cornell Medical College, New York
University of Pittsburgh Medical Center, Pittsburgh
Levine Cancer Institute, Charlotte
Emory University, Atlanta
Institut Universitaire du cancer de Toulouse-Oncopole, Toulouse
CHU de Bordeaux - Hospital Haut-Leveque, Pessac
Chu Rennes Hopital Pontchaillou, Rennes
University of Alabama Birmingham, Birmingham
Tennessee Oncology, Nashville
CHU Nantes, Nantes
Indiana University, Indianapolis
Medical College Of Wisconsin, Milwaukee
Colorado Blood Cancer Institute, Denver
University of California San Francisco, San Francisco
Hackensack University Medical Center, Hackensack
UMCG, Groningen
Maastricht University Medical Centre, Maastricht
UMCU, Utrecht
University College Hospital London, London
The Christie Nhs Foundation Trust, Manchester
Churchill Hospital, Oxford
The Royal Marsden NHS Trust Sutton, Surrey
Janssen Research & Development, LLC
INDUSTRY